Experts in Heidelberg, Germany, have developed an AI system that can classify brain tumors with unprecedented accuracy using standard microscopic tissue sections.
The research group led by Peng Wu at the Max Planck Institute of Molecular Physiology has now developed a new type of “molecular eraser” targeting the mRNA of the cancer protein NRAS.
Researchers at the Nuffield Department of Medicine, University of Oxford, together with Newcastle University’s Translational and Clinical Research Institute and the Department of Immunology at Cambridge University Hospitals NHS Foundation Trust, have identified an important driver of inflammatory bowel disease (IBD).
A new study in Nature by a team led by Doudna has uncovered a powerful new approach to selectively kill cancer cells using a CRISPR enzyme called Cas12a2.
Three commercially available radiology AI systems have shown the potential to flag early signs of breast cancer up to six years before a diagnosis, according to a study published in Radiology.
A lightweight wearable device developed by UNSW engineers could one day help people monitor their heart and breathing health from home, potentially reducing hospital visits and allowing doctors to detect problems earlier.
A case in Herkimer County, New York, led health officials to uncover local tick transmission of Borrelia mayonii, a rare Lyme disease bacterium once known only from the Midwest.
Mayo Clinic researchers and collaborators have shown that artificial intelligence (AI) can analyze routine pathology slides to help classify meningiomas, the most common primary brain tumor in adults, and predict a patient’s risk of tumor recurrence.
An anticancer medication called TLD1433, a ruthenium(II) complex that has entered Phase II trials for conditions such as non-muscle-invasive bladder cancer, is now being repurposed to address one of the biggest public health issues globally—bacterial infections.
A group of researchers at the Medical University of South Carolina (MUSC) has recently developed a new stem cell therapy with a remarkable ability to reverse new-onset type 1 diabetes (T1D) in a mouse model of the disease. The work is published in the journal Molecular Therapy.